Anzeige
Mehr »
Login
Dienstag, 04.06.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
10 Gründe für ein herausragendes Chance-Risiko-Verhältnis bei dieser Nickel-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema PHARMACOLOG

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
24.04.Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) appoints Camilla Lönn as CFO6
23.04.Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) announces its first day of trading on Nasdaq First North under its new company name2
22.04.Nasdaq Stockholm AB: Change of company name: Pharmacolog i Uppsala AB (publ) changes name to Perpetua Medical AB (publ)205As from April 23, 2024, Pharmacolog i Uppsala AB (publ)will change company name to Perpetua Medical AB (publ). ISIN Code will not change. Old company name: Pharmacolog i Uppsala AB (publ) ---------------------------------------------------- New...
► Artikel lesen
17.04.Nolsterby Invest AB has increased its holding further in Pharmacolog1
16.04.ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON APRIL 16, 20242
16.04.Pharmacolog publishes annual report for 20231
15.04.Prothena Corporation plc: Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma289Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
15.04.Nasdaq Stockholm AB: The observation status for Pharmacolog i Uppsala AB (publ) is removed224On October 13, 2023, the financial instruments of Pharmacolog i Uppsala AB (publ) (the "Company") were given observation status with reference to substantial uncertainty regarding the issuer or the...
► Artikel lesen
08.04.Nolsterby Invest AB has increased its holding in Pharmacolog1
04.04.InMed Pharmaceuticals: InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies236INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves...
► Artikel lesen
04.04.Pharmacolog announces the appointment of Anders Hedlund as interim CEO1
14.03.NOTICE TO EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)1
14.03.Pharmacolog provides update on new business direction and proposes name change2
01.03.Pharmacolog announces upcoming change in management1
27.02.Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million1
21.02.Worldwide completes pharmacy expansion at Texas clinical pharmacology unit1
21.02.Worldwide Clinical Trials Expands Clinical Pharmacology Unit Pharmacy to Enhance Customer Experience; Adds Efficiencies and Decreases Timelines218Worldwide Clinical Trials (Worldwide) a leading global, full-service contract research organization (CRO), has expanded the pharmacy at its Clinical Pharmacology Unit (CPU) in San Antonio, Texas....
► Artikel lesen
20.02.Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million-
20.02.The last day of trading with warrants of series TO3 in Pharmacolog is today, February 20, 20241
16.02.Year-end bulletin Pharmacolog 20231
Seite:  Weiter >>